On July 16, 2024, the 2024 Allergan Aesthetics China Medical Aesthetics Expert Summit, initiated and hosted by Allergan Aesthetics, was successfully held in Shanghai.At the same time, Botox® The indication for temporarily improving significant or very significant masseter muscle protrusion (hypertrophy) in adults has also been officially released.This indication was approved onIn May 2024, it was officially approved by the National Medical Products Administration. China is the first market in the world where Botox® has been approved for this indication.
It is reported that Botox®, as a Type A botulinum toxin brand that has been on the global market for over 30 years, was first approved by the U.S. FDA in 1989 for the treatment of two ocular muscle disorders in adults: blepharospasm and strabismus, making it the world's first approved Type A botulinum toxin product. In 2002, it was approved for the treatment of glabellar lines and entered the Chinese market in 2009. To date, the indications approved for Botox® in China include:1. For the treatment of blepharospasm, hemifacial spasm, and related focal dystonia in patients over 12 years old; 2. Temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults 65 years old and under; 3. Temporary improvement of moderate to severe lateral canthal lines (crow's feet) in adults;4.Temporary improvement of significant or very significant masseter muscle protrusion (hypertrophy) in adults。Allergan AestheticsAs a company under AbbVie, it is committed to the research, production, and sales of a series of advanced aesthetic brands and products, with its medical aesthetics business mainly coveringBotulinum Toxin, Hyaluronic Acid Fillers, Breast Enhancement Products, Body Shaping and Functional Skincare Productsand other fields. The predecessor of Allergan Aesthetics was Allergan, which officially entered the Chinese market in 2009. On May 8, 2020, AbbVie Inc. completed the acquisition of Allergan for $64.084 billion and officially renamed it Allergan Aesthetics. The medical aesthetics products that Allergan Aesthetics has launched in China includeBOTOX® Botulinum Toxin, Juvéderm® Hyaluronic Acid (6 fillers + 2 hydrating products), Natrelle® Breast Implants, McGhan® Breast Implants, CoolSculpting® Fat Freezing Device, and RESONIC® Pulse Device.
About Allergan Aesthetics
Allergan Aesthetics, as a company under AbbVie, is dedicated to the research, development, production, and sales of a series of advanced aesthetic brands and products, with its medical aesthetics business segment...The block mainly covers areas such as botulinum toxin, hyaluronic acid fillers, breast beautification products, body shaping, and functional skincare products.
The predecessor of Aesthetics by Allergan was Allergan, headquartered in Dublin, Ireland. Allergan officially entered the Chinese market in 2009, with its headquarters in Shanghai. On May 8, 2020, AbbVie completed the acquisition for $64.084 billion.The Acquisition of Allergan, Officially Renamed as Allergan Aesthetics。Allergan Aesthetics, an important subsidiary of AbbVie in China that operates in the global medical aesthetics biopharmaceuticals sector, has launched the following medical aesthetic products in China to date:BOTOX® Botulinum Toxin, Juvéderm® Hyaluronic Acid, Natrelle® Breast Implants, McGhan® Breast Implants, CoolSculpting® Cryolipolysis Device, RESONIC® Pulse Device。"Allergan Aesthetics in China has established a regional headquarters in Shanghai, a physician training base in Chengdu, and a new product pilot program in Lecheng., cultivating a group of high-quality talents for the industry and becoming an important force in promoting the sustainable development of China's consumer healthcare industry.On April 16, 2019, Allergan Aesthetics' first global innovation center was launched in Chengdu, China.This is the first educational base in China to provide professional training for medical aesthetics doctors. In China, Allergan Aesthetics has also established the Allergan Medical Institute (AMI) to carry out comprehensive professional education work.On September 27, 2022, Allergan Aesthetics Shanghai Innovation Center was inaugurated and put into operation.Relying on Allergan Aesthetics' global cutting-edge medical aesthetics clinical teaching practices, the Allergan Aesthetics Shanghai Innovation Center will undertake important functions in professional medical aesthetics education and product clinical application training.On November 6, 2022, Allergan Aesthetics and Hainan Boao Lecheng International Medical Tourism Pilot Zone announced a deepened cooperation.Relying on the policy advantages of Lecheng Pilot Zone, such as special access and pilot programs, we will jointly promote the landing of more Allergan Aesthetics' cutting-edge new products and technologies in Lecheng Pilot Zone, allowing a large number of patients to enjoy the fruits of scientific and technological innovation and the dividends of pilot reforms earlier.
BOTOX® by Allergan Aesthetics, an AbbVie company, was approved for marketing by the National Medical Products Administration in 2009., is the only brand of Type A botulinum toxin in China to have obtained SFDA certification, and it received the most authoritative global certification from the U.S. FDA as early as 1989. Botox has been approved by 83 countries over the past 20 years and is used for 22 different indications. It is the only injectable cosmetic product with nearly 25 years of clinical application history.
Allergan Aesthetics' Juvéderm® Hyaluronic Acid Series Products Total 7 VariantsAmong them, there are 2 products in the "U" series: Juvéderm® Volbella and Juvéderm® Ultra, which use Hylacross cross-linking technology; and 5 products in the "V" series: Juvéderm® Voluma, Juvéderm® Voluma (with Lidocaine) (two products for two indications), Juvéderm® Volift (with Lidocaine), and Juvéderm® Volite (with Lidocaine), all of which use Vycross cross-linking technology.
Under Allergan AestheticsCoolSculpting® Cryolipolysis Device,Focus on cryolipolysis technology and a full set of health and body shaping solutions,Cryolipolysis, commercially known as CoolSculpting, was launched in China on November 2, 2018. CoolSculpting is a non-invasive cryotherapy device that utilizes a non-surgical treatment process called cryolipolysis to target fat cells and cool them to temperatures that trigger apoptosis. Over time, the body naturally metabolizes these apoptotic cells, resulting in a reduction of the fat layer.
On September 18, 2023, Allergan Aesthetics released a message,Type ABotox® Successfully Developed for New Indication, Potential Treatment Option for "Moderate to Severe Platysma Prominence"；On October 24, 2023, Allergan Aesthetics, a California-based company, announced positive topline results from two pivotal Phase III clinical trials, which evaluatedType E Botulinum ToxinThe Effect of BoNT/E on Moderate to Severe Glabellar Lines M21-500 and M21-508.
On November 6, 2023, SKINMEDICA® by Allergan Aesthetics, a premium technology skincare brandOfficial Launch，Stiecq, starting from the concept of skin science, strives to create a skin anti-aging management system, with its products...Including three major series of nine products: Stretch Mark Reduction, Brightening, and Moisturizing., fully covering key areas of daily skincare such as the face, eyes, and neck.
On February 2, 2024, AbbVie announced its 2023 financial results, with total annual revenue of $54.318 billion.A 6.4% year-over-year decline, with Allergan Aesthetics' total revenue at $5.294 billion,Botox Revenue of $2.682 Billion, an increase of 2.6% year-on-year,Juvéderm Revenue of $1.378 Billion, a decrease of 3.6% year-over-year. Revenue from other aesthetic businesses was US$1.234 billion, representing a year-over-year increase of 4.4%.
On March 5, 2024, Allergan Aesthetics' Juvéderm VOLUMA XC "TemporalIndications officially approved by the U.S. FDA for temporal injection to improve moderate to severe temporal hollowing in adults over 21 years old, with nominal effects lasting up to 13 months.。It is reported that Juvéderm® VOLUMA® XC can temporarily increase volume, immediately lift and enhance the shape, contour, and structure of the temples, create a smooth transition from the cheekbones to the forehead, and balance the overall facial shape.
On April 10, 2024, the 2024 Quality Medical Aesthetics Conference with the theme "Insights into All Aspects · Boundless Quality" hosted by Allergan AestheticsConvened in Shanghai. According to reports,At the conference, Allergan Aesthetics launched several innovative projects to build quality together, including the Digital Innovation · Partnership Program, the Allergan Academy Management Training Doctor Program, and the New Quality Marketing · Decoding Personalized Aesthetics Campaign, among others.
On June 3, 2024, Allergan Aesthetics announced that itsBOTOX® for"Temporary Improvement of Significant or Very Significant Masseter Muscle Prominence (Hypertrophy) in Adults" Indication Officially Approved by the National Medical Products Administration. It is reported that the masseter muscleIndicationsIt is the first approved indication for Botox® globally and the fourth approved indication in China.
